Asbestos is a substance that can cause several life-threatening diseases, such as mesothelioma, asbestosis, and lung cancer. This dangerous mineral is no longer used as frequently as it was many years ago because of strict regulations. Unfortunately, even though asbestos is no longer being used as it was before the 1980s, there is a significant risk of people being exposed to legacy asbestos. What is Legacy Asbestos? Legacy asbestos was put in place before governments started regulating the use of asbestos, but it still presents a hazard.

Talc is a naturally occurring mineral known for its softness and versatility. This mineral is used in a wide range of consumer products. However, over the years, it has been discovered that talc can, at times, contain asbestos, a naturally occurring mineral, which, when inhaled or ingested, can cause serious illnesses, such as lung cancer and mesothelioma. If talc contains asbestos, it can contaminate products, and the end user can end up using asbestos-contaminated products without knowing and developing asbestos-related illnesses. In this article, we discuss how talc can become contaminated with asbestos.

The U.S. Food and Drug Administration (FDA) recently granted final approval of a new brand of a chemotherapy drug already in use by oncologists to treat malignant pleural mesothelioma and advanced stage non small cell lung cancer. Starting in February 2020, doctors will be allowed to prescribe Pemfexy, a type of chemotherapy drug called pemetrexed, and provide an alternative treatment to the name brand drug Alimta.

The Food and Drug Administration (FDA) recently gave approval to the first new mesothelioma drug treatment combination for patients in the last 16 years. The drug combination, Opdivo (nivolumab) in combination with Yervoy (ipilimumab) are a first-line treatment for adults with malignant pleural mesothelioma that cannot be removed by surgery. “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” said Richard Pazdur, M.D.